• Cheng-Kuang Yang, Tai-Lung Cha, Yen-Hwa Chang, Shu-Pin Huang, Jen-Tai Lin, Shian-Shiang Wang, Chao-Yuan Huang, and See-Tong Pang.
• Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taiwan.
• J Formos Med Assoc. 2023 Apr 1; 122 (4): 299308299-308.

AbstractDarolutamide, a second-generation androgen receptor inhibitor (SGARI), has been shown to increase metastasis-free survival and overall survival among men with non-metastatic castration-resistant prostate cancer (nmCRPC). Its unique chemical structure potentially provides efficacy and safety advantages over the SGARIs apalutamide and enzalutamide, which are also indicated for nmCRPC. Despite a lack of direct comparisons, the SGARIs appear to have similar efficacy, safety, and quality of life (QoL) results. Indirect evidence suggests that darolutamide is preferred for its good adverse event profile, an attribute valued by physicians, patients, and their caregivers for maintaining QoL. Darolutamide and others in its class are costly; access may be a challenge for many patients and may lead to modifications to guideline-recommended regimens.Copyright © 2023. Published by Elsevier B.V.

14 keywords...

hide…